Bolt Biotherapeutics (BOLT) Retained Earnings (2020 - 2026)
Bolt Biotherapeutics (BOLT) posted Retained Earnings of -$468.0 million for Q1 2026, down 2228580.95% sequentially from -$21000.0 in Q4 2025, and down 1170157.5% YoY from N/an in Q1 2025.
Bolt Biotherapeutics (BOLT) Retained Earnings (2020 - 2026) Analysis & Trends
Bolt Biotherapeutics has reported Retained Earnings for 7 years, with the latest figure at -$468.0 million in Q1 2026.
- Quarterly Retained Earnings fell 1170157.5% year-over-year to -$468.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$468.0 million (down 1170157.5% YoY) and the FY2025 annual result came in at -$21000.0, down 121.65% from the prior year.
- Retained Earnings retreated to -$468.0 million in Q1 2026 per BOLT's latest filing, from -$21000.0 in the prior quarter.
- Over five years, Retained Earnings peaked at $97000.0 in Q4 2024 and troughed at -$468.0 million in Q1 2026.
- A 5-year average of -$228.1 million and a median of -$295.1 million in 2022 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2025 and 2026: Retained Earnings surged 211.11% in 2025, then plunged 1170157.5% in 2026.
- Over 5 years, Retained Earnings stood at -$295.1 million in 2022, then declined by 23.45% to -$364.3 million in 2023, then surged by 100.03% to $97000.0 in 2024, then tumbled by 121.65% to -$21000.0 in 2025, then slumped by 2228580.95% to -$468.0 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$468.0 million, -$21000.0, and -$10000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Bolt Biotherapeutics | 6.10 Mn | 6.10 Mn | - | -475.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -475.74 Mn |
| Mar 31, 2026 | -468.02 Mn |
| Dec 31, 2025 | -21,000.00 |
| Sep 30, 2025 | -10,000.00 |
| Jun 30, 2025 | -447.00 Mn |
| Mar 31, 2025 | 40,000.00 |
| Dec 31, 2024 | 97,000.00 |
| Sep 30, 2024 | -411.47 Mn |
| Jun 30, 2024 | -396.29 Mn |
| Mar 31, 2024 | -36,000.00 |
| Dec 31, 2023 | -364.29 Mn |
| Sep 30, 2023 | -346.40 Mn |
| Jun 30, 2023 | -330.10 Mn |
| Mar 31, 2023 | -312.07 Mn |
| Dec 31, 2022 | -295.09 Mn |
| Sep 30, 2022 | -275.10 Mn |
| Jun 30, 2022 | -1.80 Mn |
| Mar 31, 2022 | -230.67 Mn |
| Dec 31, 2021 | -321,000.00 |
| Sep 30, 2021 | -179.83 Mn |